Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of CB-103 (Oral Pan-NOTCH Inhibitor) With Abemaciclib or Lenvatinib in Combination in Patients With NOTCH Activated Adenoid Cystic Carcinoma (CALCulus)

NCT05774899 is registered in ClinicalTrials.gov with Michael J. Dennis, MD as lead sponsor.

NCT NCT05774899
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05774899 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of CB-103 (Oral Pan-NOTCH Inhibitor) With Abemaciclib or Lenvatinib in Combination in Patients With NOTCH Activated Adenoid Cystic Carcinoma (CALCulus)
Lead sponsor
Michael J. Dennis, MD
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 1, 2023
Completion date
June 1, 2028
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenoid cystic carcinoma, metastatic adenoid cystic carcinoma, recurrent adenoid cystic carcinoma